Kureha Kagaku Kogyo Kabushiki Kaisha

Kureha Chemical Industry Company, Limited

Yoshiharu Oguchi

Kenichi Matsunaga

Chikao Yoshikumi

Takayoshi Fujii

Koichi Niimura

Takao Furusho

Masahiko Fujii

Masaaki Takahashi

Masanori Ikuzawa

Shigeaki Muto

Kunitaka Hirose

Haruhisa Hayashi

Noriyuki Toyoda

Norifumi Sugita

Junji Kakuchi

Minoru Oohara

Minoru Ohara

A binding agent for a growth factor selected from the group consisting of transforming growth factor-.beta. (TGF-.beta.) and platelet-derived growth factor (PDGF), comprising a protein-bound polysaccharide which is obtained from a fungus belonging to Coriolus, and contains about 18 to 38% by weight of proteins, and a pharmaceutically acceptable carrier or diluent is disclosed.

Binding agent for growth factor

Disclosed herein are polysaccharides extracted from marine algae and an antiviral drug containing as active ingredient polysaccharides extracted from seaweeds.

Polysaccharides and antiviral drugs containing the same as active

Disclosed herein is a pharmaceutical composition having antirheumatic activity, antithrombotic activity, analgetic activity, antipyretics activity, anti-hyperlipemic activity and anti-inflammatory activity and activities of reducing the level of blood sugar, raising the coronary blood flow, improving the capability of deformation of erythrocytes, reducing the blood pressure, ameliorating proteinuria and proteinemia and regulating production or metabolism of prostaglandins in a mammal in dosage unit form, which comprises a dosage effective to produce said activities of a glycoprotein having a molecular weight of 5000 to 300,000 as determined by ultracentrifugal method and about 18 to 38% by weight of proteins, produced by culturing a basidiomycetous fungal species belonging to the genus Coriolus, extracting the thus proliferated mycelia or fruit bodies with hot water or aqueous alkali solution and removing low molecular weight substances having a molecular weight of less than 5000 from the extract.

Pharmaceutical composition containing a glycoprotein

Disclosed herein are lectins extracted form a plant of the class Dicotyledoneae and an antiretoviral drug comprising as an active ingredient an effective amount of the lectins.

Lectins and antiretroviral drugs containing the lectins as active

Disclosed herein are an anti-tumor substance obtained by bonding an anti-tumor agent to human immunoglobulin, and a process for producing the same.

Anti-tumor substance and process for producing the same

Disclosed herein is a pharmaceutical composition having antirheumatic activity, antithrombotic activity, analgetic activity, antipyretic activity, anti-hyperlipemic activity and anti-inflammatory activity and activities of reducing the level of blood sugar, raising the coronary blood flow, improving the capability of deformation of erythrocytes, reducing the blood pressure, ameliorating proteinuria and proteinemia and regulating production or metabolism of prostaglandins in a mammal in dosage unit form, which comprises a dosage effective to produce said activities of a glycoprotein having a molecular weight of 5000 to 300000 as determined by ultracentrifugal method and about 18 to 38% by weight of proteins, produced by culturing a basidiomycetous fungal species belonging to the genus Coriolus, extracting the thus proliferated mycelia or fruit bodies with hot water or aqueous alkali solution and removing low molecular weight substances having a molecular weight of less than 5000 from the extract.

Disclosed herein is a method for examining cells, comprising subjecting the cells to an antigen-antibody reaction treatment, then measuring a pattern of the electrophoretic mobility of the cells and comparing the electrophoretic property of the cells under examination with the electrophoretic property of standard cells.

Examining cells by electrophoresis

Anti-tumor substance of immunoglobulin and melphalan and process for

Cells, particularly lymphocytes in peripheral blood or lymphatic tissues such as thymus, spleen and lymph node, are examined by measuring an electrophoretic property, such as a fraction of the number of the cells having an electrophoretic mobility within a predetermined range to the total number of the cells to be examined, with the aid of an automatic electrophoretic apparatus which is operated in a medium of the physiological conditions and by reversing the electric field, and comparing the obtained pattern of the electrophoretic property of the cells to be examined with the pattern of the electrophoretic property of normal host-cells, in order to diagnose cancer.

Method for examining cells by electrophoresis

Disclosed is a novel pharmaceutical composition having antitumor (anti-cancer) activity without causing pyrexia and anaphylaxis, formed by an amide bonding between an antibody obtained by the purification of the antibody to tumor (cancer) antigen via affinity-chromatography and an antitumor substance (anti-cancer drug).

Pharmaceutical composition having antitumor activity

Disclosed is a novel pharmaceutical composition having antitumor activity without causing pyrexia and anaphylaxis formed by an amido bonding between an antibody obtained by the purification of the antibody to tumor antigen via affinity-chromatography and an antitumor substance.

Growing community of inventors

Tokyo, Japan

Yoshiharu Oguchi